OTCM
IRME
Market cap3mUSD
Jul 11, Last price
0.05USD
1D
0.00%
Jan 2017
4,700.00%
IPO
-100.00%
Name
IR-MED Inc
Chart & Performance
Profile
IR-Med Inc., a development stage medical device company, focuses on the development of infra-red light spectroscopy combined with artificial intelligence technology platform to address diagnostic or medical needs. It is developing PressureSafe, a handheld optical monitoring device to support early detection of pressure injuries to the skin and underlying tissue primarily caused by prolonged pressure associated with bed confinement; and Nobiotics, an otoscope to support physicians with an immediate indication as to whether mid-ear infection (Otitis Media), a common malady in children. The company is headquartered in Rosh Pina, Israel.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|
2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
Income | |||||||
Revenues | |||||||
Cost of revenue | 1,941 | 4,928 | 4,637 | ||||
Unusual Expense (Income) | |||||||
NOPBT | (1,941) | (4,928) | (4,637) | ||||
NOPBT Margin | |||||||
Operating Taxes | 4,728 | ||||||
Tax Rate | |||||||
NOPAT | (1,941) | (4,928) | (9,365) | ||||
Net income | (4,909) -48.12% | (9,462) 154.29% | |||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | 755 | 1,000 | 3,625 | ||||
BB yield | -2.28% | -10.73% | |||||
Debt | |||||||
Debt current | 157 | 39 | 236 | ||||
Long-term debt | 200 | 154 | |||||
Deferred revenue | |||||||
Other long-term liabilities | 35 | ||||||
Net debt | 28 | (528) | (2,612) | ||||
Cash flow | |||||||
Cash from operating activities | (1,386) | (3,232) | (3,375) | ||||
CAPEX | (2) | (50) | |||||
Cash from investing activities | (2) | (59) | |||||
Cash from financing activities | 750 | 1,000 | 3,625 | ||||
FCF | (1,653) | (4,842) | (9,560) | ||||
Balance | |||||||
Cash | 129 | 767 | 3,002 | ||||
Long term investments | |||||||
Excess cash | 129 | 767 | 3,002 | ||||
Stockholders' equity | (14,770) | (9,862) | |||||
Invested Capital | (137) | 15,335 | 12,765 | ||||
ROIC | |||||||
ROCE | 1,416.79% | ||||||
EV | |||||||
Common stock shares outstanding | 70,759 | 69,404 | 67,578 | ||||
Price | 0.47 | 0.50 -77.27% | |||||
Market cap | 33,082 | 33,789 -75.66% | |||||
EV | 33,110 | 31,177 | |||||
EBITDA | (1,920) | (4,911) | (4,627) | ||||
EV/EBITDA | |||||||
Interest | 6 | ||||||
Interest/NOPBT |